Patrick G Enright bought $5.3M of VERA
director at Vera Therapeutics, Inc.. 250,000 shares at an average of $21.11, traded Jun 23, 2025, filed Jun 25, 2025.
Score components
- +15RoleDirector
- +25Trade size$5.3M at market
- +3Relative to holdingsHoldings up 15%
- +8Price context56% below the 52-week high
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-25-090110, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jun 23, 2025 | POpen-market purchase Class A Common Stockindirect: See footnote | +69,798 | $20.87 | $1.5M | 1,784,083 | Jun 25, 2025 |
| Jun 23, 2025 | POpen-market purchase Class A Common Stockindirect: See footnote | +139,595 | $20.87 | $2.9M | 3,569,522 | Jun 25, 2025 |
| Jun 24, 2025 | POpen-market purchase Class A Common Stockindirect: See footnote | +13,536 | $22.35 | $303k | 1,797,619 | Jun 25, 2025 |
| Jun 24, 2025 | POpen-market purchase Class A Common Stockindirect: See footnote | +27,071 | $22.35 | $605k | 3,596,593 | Jun 25, 2025 |
Related signals
Other insiders at Vera Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 11Weak | Vera Therapeutics, Inc. | Marshall Fordyce PRESIDENT AND CEO | $685k 18,500 shares | -7% | |
| 10Weak | Vera Therapeutics, Inc. | Marshall Fordyce PRESIDENT AND CEO | $650k 18,500 shares | -7% | |
| 24Weak | VERAsell Vera Therapeutics, Inc. | Robert Brenner Chief Medical Officer | $90k 2,151 shares | -4% | |
| 8Weak | Vera Therapeutics, Inc. | William D. Turner Chief Regulatory Officer | $501k 10,000 shares | -31% | |
| 36Weak | VERAbuy Vera Therapeutics, Inc. | Patrick G Enright director | $250k 5,882 shares | - | |
| 7Weak | Vera Therapeutics, Inc. | William D. Turner Chief Regulatory Officer | $453k 10,000 shares | -31% | |
| 14Weak | Vera Therapeutics, Inc. | William D. Turner Chief Regulatory Officer | $400k 10,000 shares | -31% | |
| 40Moderate | Vera Therapeutics, Inc. | Jason S Carter Chief Legal Officer | $107k 3,864 shares | -7% | |
| 30Weak | Vera Therapeutics, Inc. | Joseph R Young SVP, FINANCE, CHIEF ACCT OFFCR | $436k 15,000 shares | -24% | |
| 24Weak | Vera Therapeutics, Inc. | Marshall Fordyce PRESIDENT AND CEO | $547k 19,688 shares | -9% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.